News - Ortho Pharmaceutical
Epilepsy Drug Approved by FDA Promoted for Psychiatric Uses WASHINGTON, April 29 /PRNewswire-USNewswire/ -- American pharmaceutical manufacturers Ortho-McNeil Pharmaceutical LLC and Ortho-McNeil-Janssen Pharmaceuticals Inc., both subsidiaries of Johnson & Johnson, have agreed to pay more than $81 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Topamax, the Justice Department announced today.
- New identity reflects company's complete portfolio of Rx and specialty aesthetic products - TITUSVILLE, N.J., March 3 /PRNewswire/ -- Ortho-McNeil-Janssen Pharmaceuticals, Inc. announced today that its OrthoNeutrogena division is now Ortho Dermatologics.
Johnson & Johnson Pharmaceutical Research & Development, a subsidiary of Johnson & Johnson, has submitted a new drug application to the FDA for carisbamate, a new investigational compound for the adjunctive treatment of partial onset seizures in patients 16 years of age and older.
RARITAN, N.J., Oct. 24 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that it has submitted a New Drug Application to the U.S.